Related Experiment Video
Updated: May 23, 2026
09:40
Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
Published on: May 13, 2019
Pulmonary hypertension and right ventricular failure in left ventricular systolic dysfunction
1Advanced Heart Failure Program, Vanderbilt Heart and Vascular Institute, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. thomas.g.disalvo@vanderbilt.edu
Current Opinion in Cardiology
|April 13, 2012
Summary
Phosphodiesterase type 5 (PDE5) inhibition shows promise for treating pulmonary hypertension in patients with left ventricular systolic dysfunction (LVSD). This approach can reduce pulmonary pressures and improve heart function, offering new hope for managing this condition.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Pharmacology
Background:
- Pulmonary hypertension and right ventricular failure (RVF) are serious complications of left ventricular systolic dysfunction (LVSD).
- Standard treatments for pulmonary hypertension are often ineffective in patients with LVSD.
Purpose of the Study:
- To review the classification, pathophysiology, clinical features, and treatment of pulmonary hypertension in LVSD.
- To focus on recent studies and emerging therapeutic strategies.
Main Methods:
- Review of recent clinical evidence and studies on phosphodiesterase type 5 (PDE5) inhibition.
- Analysis of the effects of PDE5 inhibition on pulmonary pressures, cardiac remodeling, and exercise capacity.
Main Results:
- Chronic PDE5 inhibition significantly reduces pulmonary pressures and pulmonary vascular resistance (PVR).
- PDE5 inhibition reverses right and left ventricular remodeling, improving ventilator efficiency and exercise capacity.
- Improved quality of life observed in selected patients with stable, moderately symptomatic LVSD and pulmonary hypertension.
Conclusions:
- PDE5 inhibition is a promising therapeutic option for pulmonary hypertension in LVSD.
- Consider PDE5 inhibition in selected LVSD patients with persistent pulmonary hypertension or RVF despite standard therapies.
- Long-term outcome studies are needed to confirm the sustained benefits of PDE5 inhibition.
Related Concept Videos
01:20Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
01:22Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:30Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:18Pulmonary Edema II: Pathophysiology
Pulmonary edema is the accumulation of fluid in the interstitial and alveolar spaces of the lungs, impairing gas exchange and oxygen delivery. It may be cardiogenic or noncardiogenic, but both reduce oxygenation and lung compliance.Cardiogenic Pulmonary EdemaCardiogenic edema results from increased hydrostatic pressure in pulmonary capillaries, usually due to left ventricular dysfunction from myocardial infarction, heart failure, or valvular disease. Ineffective cardiac pumping causes blood to...